Compare GNT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | SCLX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 139.3M |
| IPO Year | N/A | N/A |
| Metric | GNT | SCLX |
|---|---|---|
| Price | $7.49 | $12.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 78.4K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $5.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.59 | $3.60 |
| 52 Week High | $5.40 | $34.27 |
| Indicator | GNT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 29.47 |
| Support Level | $7.52 | $12.87 |
| Resistance Level | $8.00 | $14.24 |
| Average True Range (ATR) | 0.17 | 0.99 |
| MACD | -0.04 | -0.34 |
| Stochastic Oscillator | 11.94 | 6.65 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.